The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...

While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...

Today, Industry Dive, the company behind BioPharma Dive, is combining with TechTarget’s technology websites and Informa ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

BALTIMORE, MD, December 3, 2024 — Sapio Sciences, the science-awareTM lab informatics platform, today announced that evitria, a leader in antibody expression services, has selected Sapio’s Electronic ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s ...

Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...